| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Kit ligand;Mast cell growth factor;MGF;Stem cell factor;SCF;c-Kit ligand;Soluble KIT ligand;sKITLG;KITLG;MGF, SCF; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Gene ID | |
| Host | |
| Immunogen | A synthesized peptide derived from human CDT2 Substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex required for cell cycle control, DNA damage response and translesion DNA synthesis. The DCX (DTL) complex, also named CRL4 (CDT2) complex, mediates the polyubiquitination and subsequent degradation of CDT1 and CDKN1A/p21 (CIP1) . |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-DTL antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AEBD-4; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IHC, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-CDT2 Monoclonal Antibody catalog # M01255. Tested in WB, IHC, ICC/IF, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: DTL (Kit ligand).
- Antibody format: Monoclonal; clone AEBD-4; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
DTL (protein: Glycogen synthase kinase-3 beta (gsk3b)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Ligand for the receptor-type protein-tyrosine kinase KIT. Plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KITLG/SCF binding can activate several signaling pathways. Promotes phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and subsequent activation of the kinase AKT1. KITLG/SCF and KIT also transmit signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. KITLG/SCF and KIT promote activation of STAT family members STAT1, STAT3 and STAT5. KITLG/SCF and KIT promote activation of PLCG1, leading to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5- trisphosphate. KITLG/SCF acts synergistically with other cytokines, probably interleukins. Reported cellular localization context: Isoform 1: Cell membrane; Single-pass type I membrane protein. Tissue expression notes (as provided): The alpha/alpha homodimer is expressed in embryo and in most adult tissues. The alpha/beta heterodimer and the beta/beta homodimer are found in striated muscle, and the alpha/gamma heterodimer and the gamma/gamma homodimer in neurons.
Research relevance and current trends
- Research context keywords from the source record include: Adaptive Immunity,Apoptosis,B Cells,Cancer,Cell Biology,Cytokines,Growth Factors,Immunology,Innate Immunity,Non-CD.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
- Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.
Workflow ideas (metafield): Validate DTL antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect DTL expression by Western blot in cell or tissue lysates, Detect DTL in FFPE tissue sections by immunohistochemistry, Localize DTL by immunofluorescence/immunocytochemistry in cultured cells, Quantify DTL-positive cells by flow cytometry in single-cell suspensions
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 95 kDa; calculated MW: 30899 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 95 kDa
- Cellular localization (provided): Isoform 1: Cell membrane; Single-pass type I membrane protein.
- Tissue details (provided): The alpha/alpha homodimer is expressed in embryo and in most adult tissues. The alpha/beta heterodimer and the beta/beta homodimer are found in striated muscle, and the alpha/gamma heterodimer and the gamma/gamma homodimer in neurons.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
